Abcam, ab192845, Anti-LYPD3 antibody [SP250] - N-terminal

Size: 100µL / 500µL / 1mL
Rabbit Recombinant Monoclonal LYPD3 antibody. N-terminal. Suitable for Flow Cyt, IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:SP250,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:Flow Cyt, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A/G, Purification notes-Purified from TCS by Protein A/G., Storage buffer-pH: 7.6Preservative: 0.1% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LYPD3 also known as C4.4A is a glycosylphosphatidylinositol (GPI)-anchored protein with a molecular weight of approximately 40 kDa. It belongs to the Ly6/PLAUR domain family. This protein is mainly expressed in stratified epithelia and also found in some other tissues. LYPD3 shows higher expression levels in certain cancer cell types indicating its role in tumorigenesis.
Biological function summary
LYPD3 functions in cellular adhesion and migration processes. It interacts with extracellular matrix components facilitating the movement and positioning of cells. It acts as a part of a protein complex that is important for cell communication and tissue organization. Its high expression in some cancer types suggests its involvement in processes that drive cancer progression including metastasis.
Pathways
LYPD3 participates in key signaling cascades including integrin-mediated pathways. These pathways are important for mediating cell-matrix interactions and influence cell movement and survival. LYPD3 has known interactions with integrin proteins suggesting a collaborative role that modulates cell adhesion dynamics. These interactions make it an important player in cell migration and invasion processes that are pivotal for normal physiological events and pathological conditions.
LYPD3 shows significant involvement in cancers such as squamous cell carcinoma and prostate cancer. The protein aids the metastatic spread of these cancers by promoting cell migration and invasion. It has been associated with other proteins like laminin which supports cancer cell detachment and dissemination. Understanding LYPD3's role in cancer biology helps in identifying therapeutic targets for impeding cancer progression.